Loading stock data…
BMRN
$54.06+0.15 (+0.28%)
Market ClosedLast close May 1
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioMarin Pharmaceutical Inc. in the Healthcare sector is trading at $54.06. The stock is currently 18% below its 52-week high of $66.28, remaining 4.1% below its 200-day moving average. Technical signals show neutral RSI of 44 and bullish MACD crossover, explaining why BMRN maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$54.06
Potential Downside
32.8%
Whystock Fair Value$36.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus24 analysts
Buy
Mean target$90.17+66.8%
Range$55.00 – $120.00
Fundamentals
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Paci...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.43B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.99
Beta
Defensive asset. Lower volatility than the S&P 500.
0.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.80%
Volume
Today's trading volume
1.08M
Recent News
BioMarin acquires Amicus Therapeutics for $4.8bn
With the acquisition, BioMarin adds Galafold for Fabry disease and Pombiliti+Opfolda for Pompe disease.
Snap upgraded, Pinterest downgrade: Wall Street's top analyst calls
Snap upgraded, Pinterest downgrade: Wall Street's top analyst calls
Is BioMarin Pharmaceutical (BMRN) Now Attractive After Prolonged Share Price Weakness?
Some investors are considering whether BioMarin Pharmaceutical's current share price reflects its underlying value, or if the market may be overlooking certain factors. The stock last closed at US$54.53, with returns of a 1.7% decline over 7 days, 6.8% decline over 30 days, 8.3% decline year to date, 4.0% decline over 1 year, 44.9% decline over 3 years and 31.3% decline over 5 years. Recent coverage has focused on BioMarin's role in the biotechnology space and how sentiment around its...
2 Profitable Stocks with Promising Prospects and 1 Facing Challenges
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and patented drugs.